190P - Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by th...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Colon and Rectal Cancer
Rectal Cancer
Presenter Takahide Sasaki
Citation Annals of Oncology (2016) 27 (suppl_9): ix53-ix67. 10.1093/annonc/mdw581
Authors T. Sasaki1, S. Yuki2, Y. Kawamoto3, K. Harada3, T. Meguro1, T. Miyagishima4, M. Nakamura5, A. Sato6, I. Iwanaga7, M. Tateyama8, K. Hatanaka9, K. Eto10, H. Okuda11, O. Muto12, M. Abe13, A. Oba14, S. Kato15, K. Miyashita16, Y. Sakata17, Y. Komatsu3
  • 1Internal Medicine, Hokkaido Gastroenterology Hospital, 065-0041 - Sapporo/JP
  • 2Gastroenterology And Hepatology, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 3Cancer Center, Hokkaido University Hospital, 060-8638 - Sapporo/JP
  • 4Medical Oncology, Kushiro Rosai Hospital, 085-8533 - Kushiro/JP
  • 5Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 6Medical Oncology, Hirosaki University Hospital, 036-8562 - Hirosaki/JP
  • 7Medical Oncology, Japanese Red Cross Kitami Hospital, 090-0026 - Kitami/JP
  • 8Internal Medicine, Tomakomai Nisshou Hospital, 053-0803 - Tomakomai/JP
  • 9Gastroenterology, Hakodate Municipal Hospital, 041-0821 - Hakodate/JP
  • 10Gastroenterology, Tomakomai City Hospital, 053-0034 - Tomakomai/JP
  • 11Medical Oncology, Keiyukai Sapporo Hospital, 003-0027 - Sapporo/JP
  • 12Medical Oncology, Japanese Red Cross Akita Hospital, Akita/JP
  • 13Medical Oncology, Sapporo Kosei General Hospital, Sapporo/JP
  • 14Gastroenterology, Iwamizawa Municipal General Hospital, Iwamizawa/JP
  • 15Gastroenterology, Sapporo Hokuyu Hospital, Sapporo/JP
  • 16Gastroenterology, Aiiku Hospital, Sapporo/JP
  • 17Ceo, Misawa City Hospital, Misawa/JP

Abstract

Background

The Glasgow Prognostic Score (GPS), combination of C-reactive protein and albumin, has reported its prognostic value in metastatic colorectal cancer patients receiving cytotoxic agents. However, the validity of the GPS has not been reported in patients treated with bevacizumab (Bev)-based first line chemotherapy.

Methods

115 patients with mCRC treated with Bev contained first line chemotherapy were registered from 15 centers in Japan. Univariate and multivariate analysis for overall survival (OS) were performed using patient characteristics. Survival analyses were performed with the Kaplan-Meier method, log-rank test and the Cox proportional hazards model. The analysis was also designed to determine whether the GPS could be extended to progression-free survival (PFS).

Results

All data were available for prognostic categorization in 97 patients. Patients with the GPS of 0, 1 and 2 were 58, 23, and 16, respectively. The pts characteristics between 0 and 1/2 were generally balanced except for prior colorectomy (70.7% in 0, 51.3% in 1/2; p = 0.058), disease status (primary unresectable) (79.3% in 0, 97.4% in 1/2; p = 0.013), liver metastasis (58.6% in 0, 84.6% in 1/2; p = 0.007), KRAS exon2 status (wild) (70.7% in 0, 51.3% in 1/2; p = 0.058) and median number of metastatic organ (mean; 1.78 in 0, 2.21 in 1/2; p = 0.040). The distribution and median OS/PFS for the GPS were as follows: 0 (n = 58; 29.9/10.4 months), 1/2 (n = 39; 17.0/7.3 months). For OS and PFS, there were significant difference between 0 and 1/2 (p 

Conclusions

It was shown that GPS might provide valuable information in the bevacizumab combined first line chemotherapy for patients with mCRC.

Clinical trial indentification

This trial don't have the trial protocol number.

Legal entity responsible for the study

Nonprofit Organization: Hokkaido Gastrointestinal Cancer Study Group

Funding

Nonprofit Organization: Hokkaido Gastrointestinal Cancer Study Group

Disclosure

T. Sasaki: Honoraria: Chugai Pharmaceutical. S. Yuki: Honoraria: Taiho Pharmaceutical, Merck Serono, Bristol-Myers Squibb, Takeda Pharmaceutical, Chugai Pharmaceutical, Bayer Yakuhin, Eli Lilly Japan. Y. Sakata: Honoraria: Taiho Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Merck SeronoOno Pharmaceutical, Nikkei Business Publications. Y. Komatsu: Honoraria and/or Research fund: Taiho Pharmaceutical, Yakult Honsha, Chugai Pharmaceutical, Merck Serono, Pfizer Japan, Ono Pharmaceutical, Daiichi Sankyo, Takeda Pharmaceutical, Eli Lilly Japan, Novartis Pharma, Kureha Corporation. All other authors have declared no conflicts of interest.